Einfach Bitcoin kaufen: Mit dem Code "FINANZEN" sparen Sie 21% der Gebühren für 6 Monate bei Coinfinity. Jetzt loslegen -w-
19.12.2016 16:41:00

Orexo to Present at the Annual Biotech Showcase Conference, San Francisco

UPPSALA, Sweden, Dec 19, 2016 /PRNewswire/ --

Orexo AB (publ.), announced today that it will present at the 9th Annual Biotech Showcase Conference being held January 9-11, 2017 in San Francisco, CA.

Nikolaj Sørensen, President and CEO of Orexo AB, will present the business, focusing on the driving forces behind the global opioid addiction treatment market, the development of Zubsolv® in the US and the progress towards launching in the rest of the world. An overview will also be given of Orexo's pipeline of innovative product development programs and the company's recent strong financial development.

 

Event:

9th Annual Biotech   Showcase Conference

Date:

 

Monday, January 9, 2017 

Time:

 

11:00 am (Pacific Time) 

Location:

 

Room 3 (Ballroom Level), Parc 55   Hotel, San Francisco, CA 

If you would like to get an update about Orexo today please visit www.orexo.comfor the most recent investor presentations, financial reports and our investor dialogue. In addition a fresh interview with Nikolaj Sørensen is available at www.orexo.com.

For more information please contact:

 

 

Orexo AB (publ.)



 

Lena Wange, IR & Communications Manager

Tirth Patel, Edison Advisors


Tel: +46 18 780 88 00

Tel: +1 646 653 7035


Email: ir@orexo.com

          Email: tpatel@edisongroup.com





About Orexo
Orexo is a specialty pharmaceutical company commercializing its proprietary product Zubsolv® for treatment of opioid dependence in the US. Zubsolv is an advanced formulation of buprenorphine and naloxone using Orexo's unique knowledge and expertise in sublingual drug delivery. R&D is focusing on reformulation of known substances to new improved products that meet great unmet medical needs by using its patented proprietary technologies. Orexo's share is listed on Nasdaq Stockholm Exchange Mid Cap (STO:ORX) and is available as ADRs on OTCQX (ORXOY) in the US. Orexo's global headquarters and R&D are based in Uppsala, Sweden.

For more information about Orexo, please visit www.orexo.com or follow us on Twitter or LinkedIn.
For further information about Zubsolv in the US, please visit www.zubsolv.com

The information was submitted for publication at 4:15pm CET, December 19, 2016

This information was brought to you by Cision http://news.cision.com
http://news.cision.com/orexo/r/orexo-to-present-at-the-annual-biotech-showcase-conference--san-francisco,c2153316

The following files are available for download:

http://mb.cision.com/Main/694/2153316/605965.pdf

PDF

SOURCE Orexo

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/orexo-to-present-at-the-annual-biotech-showcase-conference-san-francisco-300381080.html

SOURCE Orexo

Analysen zu Orexo ABShsmehr Analysen

Eintrag hinzufügen
Hinweis: Sie möchten dieses Wertpapier günstig handeln? Sparen Sie sich unnötige Gebühren! Bei finanzen.net Brokerage handeln Sie Ihre Wertpapiere für nur 5 Euro Orderprovision* pro Trade? Hier informieren!
Es ist ein Fehler aufgetreten!

Aktien in diesem Artikel

Orexo ABShs 1,05 3,96% Orexo ABShs